The dangerous legacy of COVID-19: A rise in antimicrobial resistance

  03 April 2020

The widespread, inadvertent use of antimicrobial drugs in this pandemic could leave us with another, more dangerous legacy: a dramatic increase in drug-resistant infections.

Drug-resistant infections (often referred to as “superbugs”) emerge through a complex interplay of humans, animals and the environment. Excessive and increased use of antibiotics over several decades has led to a growing list of organisms that no longer respond to treatment. It’s called antimicrobial resistance, or AMR. It costs us $1.4-billion annually and, before this pandemic, it was predicted to cause the loss of 256,000 Canadian lives by 2050.

Today, we are watching the alarming spread of the new coronavirus. With no proven treatment, it marches, unbridled, across the globe. In the same way, drug-resistant bacteria could lead to the frightening spread of bacterial infections that would no longer respond to currently reliable antibiotics.

Further reading: The Globe and Mail
Author(s): ANDREW MORRIS AND GERRY WRIGHT
Effective Surveillance   Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

More information

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed